Agence fédérale des médicaments et des produits de santé
Eurostation II - Place Victor Horta 40/40
1060 Bruxelles
www.afmps.be

DG Pré/R&D

Caroline Van Droogenbroeck
Tél. : 02/528 43 28
Fax : 02/528 40 01
e-mail : caroline.vandroogenbroeck@fagg.be

Pharm-Olam International (Belgium) BVBA
[redacted]
Dorp 14a
3272 Testelt

Votre lettre du	Vos références	Nos références	Annexe(s)	Date
		AFMPS/DGPRE/R&D/VDC		

Dossier OGM: B/BE/20/BVW2 (2019-001890-98): A Phase 1b/2 Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-vectored Multigenotype High Risk Human Papillomavirus (hrHPV) Vaccine and Modified Vaccinia Ankara (MVA)-vectored Multigenotype hrHPV Vaccine in Women with Low-grade HPV-related Cervical Lesions

Cher [redacted],

Par la présente, nous vous informons que l'autorisation imposée en vertu de l'arrêté royal du 21 février 2005 règlementant la dissémination volontaire dans l'environnement ainsi que la mise sur le marché d'organismes génétiquement modifiés ou de produits en contenant vous est accordée sur base de l'avis favorable du Conseil de Biosécurité daté du 5 juin 2020, et ce, aux conditions reprises dans la conclusion de l'avis précité, c'est-à-dire :

"- *The notifier and the investigators must strictly apply all the control, personal protection, decontamination and disinfection measures during handling or administration of the investigational therapeutic ChAdOx1-HPV and MVA-HPV vaccines as described in the updated application form (version 3) (including ERA) as submitted on 02 June 2020.*

- *Any protocol amendment has to be previously approved by the Competent Authority.*

- *The notifier is responsible to verify that each study centre has qualified personnel experienced in handling infectious material and that the investigator has the required authorizations to perform the clinical trial activities inside the hospital (laboratory, pharmacy, hospital room, consultation room...) according to the Regional Decrees transposing Directive 2009/41/EC on Contained use of genetically modified micro-organisms.*

- *The Biosafety Advisory Council should be informed within two weeks when the first patient starts the treatment and the last patient receives the last treatment.*

- *At the latest six months after the last visit of the last patient included in the trial, the notifier must send to the competent authority at the attention of the Biosafety Council a report with details concerning the biosafety aspects of the project. This report will at least contain:*

o The total number of patients included in the trial and the number of patients included in Belgium;

o A summary of all adverse events marked by the investigators as probably or definitely related to the study medication;

o A report on the accidental releases, if any, of ChAdOx1-HPV and MVA-HPV."

Sincères salutations,

Maggie De Block
Ministre des Affaires Sociales, de la Santé publique, de l'Asile et de la Migration

Marie Christine Marghem
Ministre de l'Energie, de l'Environnement et du Développement durable